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Letters to the EditorTime is a crucial factor for the use of oncological treatment
for post-transplantation recurrence of hepatocellular carcinomaThe work of Sposito et al. represents a major contribution in
clarifying the role of sorafenib for hepatocellular carcinoma
post-transplant recurrence. The article has shown compelling
evidence of its efﬁcacy, and above all, safety. Although all factors
have been controlled and the use of sorafenib was the only factor
inﬂuencing survival, we now add that time from transplantation
to recurrence also impacts on the prescription of sorafenib.
Longer periods between transplantation and recurrence may
allow patients to recover from transplantation, to improve their
performance status, and, most importantly, to reduce their base-
line immunosuppression, which is suggested as ﬁrst-line treat-
ment in the algorithm proposed by Toso et al. [2]. Furthermore,
recurrence in the early post-operative setting possibly represents
a distinct clinical entity from later recurrence. In the setting of
early recurrence, a highly aggressive behavior of the tumor
allows little, if any, therapeutic endeavors to control disease
progression.
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We have read with great interest the work of Sposito et al., in
which they demonstrated a survival beneﬁt for patients who
use sorafenib for recurrent hepatocellular carcinoma after liver
transplantation [1]. As pointed out by the authors and in the ele-
gant editorial by Toso et al., there is an absence of solid data to
guide evidence-based practice for the practitioner managing
patients with this complication of the disease [1,2]. Moreover,
due to the infrequent nature of the problem, it might be difﬁcult
to conduct well-powered randomized control trials in this set-
ting. Another possibility is that patients with early recurrence
may not only have a higher baseline tumor load, but also more
aggressive biology. This assumption is strengthened by the obser-
vation that patients with early recurrence of hepatocellular carci-
noma have larger lesions and more undifferentiated tumors than
those with later recurrence [3,4]. Other authors have also sug-
gested that a longer time from transplant to recurrence might
have an impact on prognosis [5–7].
To test this hypothesis, our group has performed a retrospec-
tive analysis of patients who underwent liver transplantation at
our institution between May 2005 and March 2013. In this cohort
of 919 consecutive patients, 257 presented with hepatocellular
carcinoma on their liver explants, and 20 patients developed
post-operative recurrence during an average follow-up of
24.3 ± 20.2 months.
Twelve patients (60%) had early post-transplant recurrence
(within the ﬁrst year of transplantation), and 8 patients (40%)
had late post-transplant recurrence (after the ﬁrst year of trans-
plantation). Patients with recurrence of the tumor after the ﬁrst
year after liver transplantation have shown a very distinct proﬁle
compared to those with earlier recurrence. The frequencies of low
grade tumors (7 patients with late recurrence vs. 1 patient with
early recurrence, p = 0.000), and microvascular invasion (1
patient with late recurrence vs. 10 patients with late recurrence,
p = 0.005) were signiﬁcantly different when time to recurrence
was considered. We also observed a trend towards a higher fre-
quency of macrovascular invasion in the group with early recur-
rence (0 patients with late recurrence vs. 5 patients with early
recurrence, p = 0.055). The group with late recurrence had similar
immunosuppression (tacrolimus based) and was much more
likely to receive some form of oncological treatment (OR 35.0;
CI 95%: 2.6–465.3, p = 0.007) than those with early recurrences.
In this circumstance sorafenib was the mainstay of therapy,
either alone (6 cases) or in association with sirolimus (3 cases).
In the same fashion as in Sposito et al., patients who received
oncological treatment survived longer (452.0 ± 353.7 days vs.
93.8 ± 59.8 days, p = 0.004) than those who received the best sup-
portive care.[5] Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y,
et al. Improved results of a surgical resection forthe recurrence of hepato-
cellular carcinoma after living donor liver transplantation. Ann Surg Oncol
2010;17:2283–2289.
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Reply to: ‘‘Time is a crucial factor for the use of oncological treatment
for post-transplantation recurrence of hepatocellular carcinoma’’
To the Editor:
We thank Dr. Felga and colleagues for their comments on our
article demonstrating the efﬁcacy of sorafenib treatment in case
of recurrent hepatocellular carcinoma (HCC) after liver transplan-
tation (LT) [1]. In their experience with 20 of such patients in
Brazil they observed that time-to-recurrence (TTR) after LT might
be inﬂuenced by adverse baseline tumor biology – i.e., G3 tumors
and presence of macrovascular invasion – and tumor load,
suggesting that early recurrences within 1 year after LT were
characterized by a worse prognosis, while patients with later
recurrences were more prone to receive some form of HCC
treatment and had a higher median survival.
Indeed, we thank for the opportunity to add to our previous
report a few comments on the supposed differences among early
vs. late recurrences after LT. Differently from Dr. Felga et al., we
did not ﬁnd that HCC factors such as tumor load (within/beyond
Milan criteria at radiology and pathology), presence of microvas-
cular invasion (mVI) and presence of microsatellites were
correlated with TTR (with p = 0.217, 0.510, 0.128, and 0.510
respectively at the Pearson Chi-square test). Only a higher num-
ber of nodules per se – evaluated as a continuous variable at
pre-LT radiology and at histology – appeared to be associated
with an earlier recurrence (p = 0.019 and 0.036 respectively at
the Kruskal-Wallis test). Therefore, even if the aforementioned
HCC characteristics are associated with the probability of tumor
recurrence after LT [2], they are apparently poor predictors of
the TTR after LT.
Although TTR is not predictable, timing and pattern of the
observed recurrences may happen to be correlated. In our series,
patients with early recurrence suffered that in multiple organs
more frequently than patients with a later recurrence (63.6% vs.
28.6%, p = 0.43). This resulted in a reduced eligibility to curative
treatments – such as surgical resection or radiofrequency abla-
tion – that were applied only in 18.2% of those with early recur-
rence vs. 75% of late recurring patients (p = 0.001), since also the
median time to untreatable progression/presentation was signif-
icantly different among groups [0.5 months (0.5–54.8) vs.
11.1 months (0.5–77.4), p = 0.131 respectively]. As brilliantly sta-
ted by Toso et al. [3], early recurrences may be linked to remain-
ing extrahepatic HCCs deposits left at the time of LT, or result
from the post-transplant engraftment of aggressive circulating
HCC clones. Such a tumor aggressiveness, that inﬂuences treat-
ment applicability and patients outcome, has been previously
demonstrated by different authors [4,5] and conﬁrmed herein
by Felga et al.
In our recent paper, we observed that the more indolent
course of late HCC recurrences, occurring more than 2 years after
LT, is associated with a reduction in the risk of death of more than
70% if compared to early recurrent patients. Noteworthy, the
median TTR of those 5 patients of our series remaining alive
and cured after surgical resection of their recurring HCC
approached 5 years (58.7 months). In these patients HCC recur-
rence is probably the result of the reactivation of a few dormant
HCC cells, engrafted at the time of LT: in such circumstances a
prompt surgical removal may be associated with some chance
of cure. Conversely, when facing early recurrences after LT, an
aggressive surgical treatment may be useless and even harmful
considering the high risk of further growth of occult disease. As
suggested [3], the ﬁrst step in the treatment of an early intrahe-
patic recurrence may be a loco-regional treatment, used as a test
of time in order to observe potential progression in other sites. In
the instance of an early recurrence emerging in multiple organs,
or when facing an untreatable progression, we recommend the
use of sorafenib at the onset of recurrence, considering its safety
and possible beneﬁt in survival [1,6].
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